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The use of biomaterials and nanosystems in antigen delivery has played a major role 
in the development of novel vaccine formulations in the last few decades. In an effort 
to gain a deeper understanding of the interactions between these systems and immu-
nocompetent cells, we describe here a systematic in vitro and in vivo study on three 
types of polymeric nanocapsules (NCs). These carriers, which contained protamine 
(PR), polyarginine (PARG), or chitosan (CS) in the external shell, and their corresponding 
nanoemulsion were prepared, and their main physicochemical properties were character-
ized. The particles had a mean particle size in the range 250–450 nm and a positive zeta 
potential (~30–40 mV). The interaction of the nanosystems with different components 
of the immune system were investigated by measuring cellular uptake, reactive oxygen 
species production, activation of the complement cascade, cytokine secretion profile, 
and MAP kinases/nuclear factor κB activation. The results of these in vitro cell experi-
ments showed that the NC formulations that included the arginine-rich polymers (PR and 
PARG) showed a superior ability to trigger different immune processes. Considering this 
finding, protamine and polyarginine nanocapsules (PR and PARG NCs) were selected 
to assess the association of the recombinant hepatitis B surface antigen (rHBsAg) as a 
model antigen to evaluate their ability to produce a protective immune response in mice. 
In this case, the results showed that PR NCs elicited higher IgG levels than PARG NCs 
and that this IgG response was a combination of anti-rHBsAg IgG1/IgG2a. This work 
highlights the potential of PR NCs for antigen delivery as an alternative to other positively 
charged nanocarriers.
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inTrODUcTiOn
Vaccination is one of the most cost-effective health interventions for the prophylaxis of infectious 
diseases. Conventional vaccines use inactivated or attenuated pathogens—or even subunits of these 
organisms, such as toxoids and carbohydrates—as antigens (1). Unfortunately, the immune protec-
tion provided by these subunit vaccines, even with classical adjuvants, i.e., alum, is often insufficient. 
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Moreover, these vaccines suffer from additional problems, such as 
limited storage stability and the need for multiple-dose injection 
schemes to achieve effective protection. Thus, vaccine develop-
ment has been required to move toward a new generation of vac-
cines that could provide better and more sustainable protective 
immune responses (2).
Interest in the use of innovative antigens such as recombinant 
proteins, peptides, or nucleic acids has increased in the last few 
decades (3–5). In spite of the many advantages of these new 
vaccine prototypes, including an enhanced immunogenicity/
risk ratio profile and easier manufacture, the development of 
improved adjuvants that may enhance the potency of these vac-
cines has become essential. Several inmunostimulant molecules 
(i.e., cytokines, toll-like receptor ligands, toxins, or saponins) and 
antigen delivery systems (i.e., virosomes, emulsions, or nanopar-
ticles) are among the potential adjuvants studied in this scope. 
In particular, the use of nanosystems has attracted significant 
attention, especially for vaccines requiring an improvement in 
cell-mediated immune responses (6).
Polymer- and lipid-based nanoparticles have been the most 
widely explored nanosystems in vaccination. It has already been 
reported that nanostructures are able to enhance both B and T cell 
responses due to their similarity with viruses in terms of size and 
surface properties (7). In addition, due to their prolonged pres-
entation to the immune system, these nanostructures can induce 
long-lasting immune responses, thereby offering the possibility 
of decreasing the number of doses required to achieve protective 
antibody levels. Moreover, nanoparticle formulations have shown 
the ability to avoid overactivation of the immune response and, 
simultaneously, to trigger the production of pro-inflammatory 
cytokines (8).
Our group has developed a number of antigen delivery 
technologies and validated them using rHBsAg as a model 
antigen. Namely, we have produced various chitosan-based 
nanocarriers, including chitosan-coated PLGA nanoparticles 
(9), CS nanoparticles (10), and CS nanocapsules (NCs) (11). 
More recently, we also developed arginine-rich based (PARG 
and PR) NCs (12) and nanoparticles including different anionic 
polymers (dextran sulfate and alginate) (13). Overall, the in vivo 
administration of these nanocarriers through nasal or paren-
teral routes has led to significant IgG responses in mice (11, 14). 
Interestingly, the differences obtained in the elicited immune 
responses highlighted the importance of the composition of 
the nanosystem, especially concerning the type of biopolymer 
exposed on the nanoparticle surface.
The aim of the work described here was to gain an under-
standing of the role of the polymeric shell of NCs in their 
interaction with immune cells. For this purpose, three types 
of NCs with different coating polymers (PARG, PR, and CS), 
and the corresponding nanoemulsion (NE), were compared in 
a systematic study. This included the in vitro evaluation of cel-
lular uptake, the reactive oxygen species (ROS) production, the 
activation of the complement cascade, the cytokine secretion 
profile, the MAP kinases/nuclear factor κB (NFκB) activation, 
and gene expression. The influence of size, composition of the 
outer shell layer, and superficial charge in these processes were 
analyzed, and the two most promising prototypes were selected 
to perform in vivo studies with the rHBsAg antigen. In addi-
tion to the systematic study, the four different prototypes were 
converted into freeze-dried products, to enhance the stability 
of the formulations under storage and avoid the need of the 
maintenance of the cold chain. The physicochemical characteri-




Three polymers were used: protamine from Yuki Gosei Kogyo, 
Ltd. Company (Japan), chitosan hydrochloride salt (Protasan 
UP CL113 deacetylation degree of 75–90%, Mw: 125 kDa) was 
purchased from NovaMatrix (Sandvika, Norway) and polyargi-
nine (PARG) (Mw 5–15 kDa) was obtained from Sigma-Aldrich 
(Barcelona, Spain). Miglyol® 812, a mixture of three different 
triglycerides of medium chain fatty acids, was obtained from 
Sasol GmbH (Witten, Germany). Recombinant hepatitis B sur-
face antigen (rHBsAg) (Mw 24 kDa) in an aqueous suspension 
[0.16 mg/mL in phosphate-buffered saline (PBS)] was kindly 
donated by Shantha Biotechnics Limited (Hyderabad, India). 
PEG-stearate (Simulsol® M52) was purchased from Invitrogen 
(UK). Cobra venom factor (CVF) was supplied by Quidel 
Corporation (USA), and the PVDF membranes were obtained 
from Bio-Rad (USA).
Aluminum hydroxide, sodium hydroxide, rhodamine 6G, 
Triton 100x, PBS, 5-bromo-4-chloro-3-indolyl phosphate (BCIP), 
glycerol, sodium cholate, 2ʹ,7-dichlorofluorescein diacetate 
(DCFH-DA), lipopolysaccharide (LPS), phorbol myristate acetate 
(PMA), and phytohemagglutinin (PHA) were all obtained from 
Sigma-Aldrich (USA).
Cell culture media (DMEM and RPMI 1640) and the antibi-
otics penicillin and streptomycin were supplied by Gibco (Life 
Technologies, Scotland). Heat inactivated fetal bovine serum 
(FBS) and Accutase® were purchased from PAA Laboratories 
(Austria), and Ficoll-Hypaque was obtained from GE Healthcare 
(Sweden).
Antibodies
Enzyme-Linked Immunosorbent Assay (ELISA) for 
Recombinant Hepatitis B Antigen (rHBsAg)
Enzyme-linked immunosorbent assay kit (Murex HBsAg Version 
3) was obtained from Murex Biotech Ltd. (Dartford, UK), and 
the polyclonal chicken antibodies against HBsAg were purchased 
from Abcam (UK). Mouse and rabbit antibodies against HBsAg 
used in the ELISA test were purchased from Acris Antibodies 
GmbH (Hiddenhausen, Germany) and Biokit (Barcelona, Spain), 
respectively. Secondary mouse antibodies against IgG, IgG1, 
IgG2a conjugated with horseradish peroxidase (HRP) were 
acquired from Southern Biotech (USA).
Western Blot and ELISA for Complement Factors (C3 and C5)
Polyclonal secondary antibodies used in the Western blot assay 
were purchased from Dako (Glostrup, Denmark), and the 
monoclonal antibody (mAb) against complement factor C3 
was obtained from Abcam (UK). Human C5a ELISA Kit II BD 
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OptEIA™ used for the detection of complement factor C5 was 
purchased from BD Biosciences Pharmingen (CA, USA).
Flow Cytometry: Cell Markers and Cytokines
Monoclonal antibodies for flow cytometry assays were anti- 
CD3-PECy5.5, anti-CD19-PECy5.5 (Southern Biotech, AL, 
USA), anti-HLA-DR-FITC (Beckman Coulter, USA), and 
anti-CD71-PE (NIT Zipper, Nanoimmunotech, Spain).
Cytokine detection was performed with the FlowCytomix kit 
Th1/Th2 from eBioscience (San Diego, CA, USA).
Analysis of Kinase Routes by Western Blot
Rabbit monoclonal antihuman p-extracellular signal-regulated 
kinase (ERK), p-p38, p-SAP/JNK, IKBα, and goat anti-rabbit 
IgG-HRP antibodies used for the Western blot analysis were sup-
plied by Cell Signaling Tech. (Danvers, MA, USA), and the anti-
GAPDH antibody was obtained from Sigma-Aldrich (Barcelona, 
Spain).
nanoparticle Preparation
Nanocapsules were prepared using the solvent displacement 
technique previously described by our research group (15). 
Briefly, a mixture of 12  mg of PEG-st and 5  mg of sodium 
cholate was dissolved in 0.750  mL of ethanol, followed by the 
addition of 62.5 µL of Miglyol® 812 to the previous mixture. The 
volume of the organic phase was increased by adding 4.25 mL 
of acetone. This organic phase was added to an aqueous phase 
composed of 10 mL of a solution of 0.05% w/v of PR, PARG, or 
CS for the preparation of the PR and CS NCs or 10 mL of milliQ 
water in the case of the control, uncoated NE. In all cases, the 
nanostructures were spontaneously formed upon diffusion of the 
solvents. The nanostructures were isolated by ultracentrifugation 
of the samples at 61,690 g for 1 h at 15°C (Optoma TM L-90K 
Ultracentrifuge, Beckman Coulter, USA).
Physicochemical characterization  
of the nanostructures
The hydrodynamic diameter and polydispersity index (PDI) of 
the NCs and the corresponding NE were measured by photon 
correlation spectroscopy. Zeta potential was determined by laser-
Doppler anemometry (Zetasizer®, NanoZS, Malvern Instruments, 
Malvern, UK). Samples were measured after diluting in milliQ 
water (970 µL of water: 30 μL of NCs) or in 1 mM KCl for size 
and zeta potential, respectively.
Fluorescent labeling of the nanocarriers
Nanocapsules were prepared as described in Section “Nanoparticle 
Preparation” by adding an aliquot of the chromophores to the oily 
phase. Rhodamine B, rhodamine 6G, and DiD (1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindodicarbocyanine, 4-chlorobenzenesul-
fonate salt) were selected as fluorescent markers at two different 
concentrations (10 and 50 µg/mL dissolved in ethanol), evaluat-
ing both the influence of the nature of the chromophore and its 
concentration. The evaluation of the encapsulation efficiency of 
the chromophores was carried out indirectly by quantifying the 
non-encapsulated fluorophore remaining in the undernatants 
after the centrifugation step. Rhodamines were measured at an 
emission wavelength of 590  nm (LB 940 Multimode Reader 
Mithras, Berthold Technologies GmbH & Co KG, Germany); 
UV–VIS spectroscopy at λ = 646 nm (Du-BoLife Science UV/VIS 
Beckman Coulter) was used to quantify DiD. The three different 
fluorophores were incorporated into the NE, PR and CS NCs, 
assuming no differences in the release and the encapsulation effi-
ciency between the PR and the PARG NCs. The evaluation of the 
loading efficiency and release profile of the different fluorescent 
dyes are disclosed in Supplementary Material (Supplementary 
Figure 1 and Supplementary Table 1).
association of hepatitis B surface antigen 
(rhBsag) With the ncs
PR and PARG NCs, prepared as described in Section 
“Nanoparticle preparation,” were incubated with rHBsAg in 
equal volumes at a mass ratio of 4:1 (theoretical concentration 
of the cationic polymer adsorbed on the NC surface:rHBsAg) 
to achieve adsorption onto the polymeric corona. The process 
was performed under mild conditions (RT, 1 h), and the loaded 
NCs were subsequently isolated (30 min, 12,872 g, 15°C). The 
amount of rHBsAg associated to the NCs was indirectly quanti-
fied by measuring the concentration of antigen remaining in 
the undernatant after the ultracentrifugation step. An ELISA 
commercial kit was used to quantify the rHBsAg concentration 
in the samples, according to the manufacturer’s instructions. 
The association efficiency for rHBsAg (A.E.%) was calculated 
indirectly as the difference between the concentration of free 
antigen detected in the supernatant and the total concentration 
in the initial suspension.
Freeze Drying of the ncs
To obtain a lyophilized product, preliminary studies were car-
ried out to determine the best conditions to preserve the original 
physicochemical properties of the prototypes upon reconstitu-
tion (Supplementary Figure 2). The conversion into a dry pow-
der was performed using a freeze-drying process (Genesis SQ 
Freeze dryer, Virtis, USA) (11). The studies were conducted with 
aliquots of the four nanosystems in a range of concentrations 
(0.25–1% w/v) both with and without cryoprotectant (glucose, 
trehalose, and sucrose at 5 and 10% w/v). Based on the results 
obtained, and to standardize the process conditions for the 
four prototypes, a solution of each of the different nanosystems 
(0.75% w/v) was frozen overnight at −20°C in the presence of 
sucrose as cryoprotectant (10% w/v). Subsequently, the samples 
were transferred to the lyophilizer (Genesis SQ Freeze Drier, 
Virtis, USA) and submitted to an initial drying step for 24 h at 
−35°C and 2–10 mTorr followed by a second and a third drying 
step (24 h, 0°C and 16 h, 20°C, respectively). After the process, 
the freeze-dried cake had an overall good aspect and could be 
resuspended swiftly in ultrapure water.
activation of the complement cascade
The activation of the complement cascade upon contact with 
the different nanostructures was analyzed by two methods: 
degradation of the complement C3 factor by Western blot and 
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quantification of the C5a levels by ELISA. A pool of human 
plasma from healthy donors was incubated with different 
concentrations of nanosystems (10, 100, and 1,000  µg/mL of 
the constituent polymer and the corresponding amount of 
NE) and veronal buffer (pH 7.4). An aliquot of 50 µL of each 
formulation and controls were incubated at 37°C for 1 h. CVF 
and PBS were used as positive and negative controls, respec-
tively. After the incubation step, samples were centrifuged at 
16,000 g for 30 min to separate the nanosystems from the other 
components.
Qualitative Determination by Western Blot
After the centrifugation step, supernatants containing the 
complement proteins were loaded onto a 10% SDS-PAGE gel 
and transferred to a PVDF membrane with the Transblot-Turbo 
Transfer System (Bio-Rad, Hercules, CA, USA). Membranes were 
blocked overnight at 4°C with TBST with 5% of non-fat dried 
milk. Membranes were then incubated with a mouse mAb against 
human C3 (1:1,000) (90 min, RT). A secondary incubation step 
was performed under the same conditions (90  min, RT) with 
secondary polyclonal goat anti-mouse IgG antibodies conjugated 
with alkaline phosphatase (1:2,000). Intensive washes were car-
ried out between all steps. Membranes were revealed with BCIP. 
To quantify the degradation, the intensity of the lower band was 
normalized to the negative control, where some basal C3 degra-
dation was observed.
Quantitative Determination by ELISA
An ELISA assay was performed using the Human C5a ELISA Kit 
II to confirm the activation of the complement cascade quantify-
ing C5a factor levels. Briefly, standards and samples were added 
for 2 h at RT to the wells previously coated with an mAb against 
the C5a factor. After several washes, wells were incubated for 
1 h with a mixture of biotinylated antihuman C5a antibody and 
streptavidin-HRP. Intensive washes were performed between 
all these steps. To detect the presence of the antibody-antigen 
complexes, TMB Substrate Reagent was added. After 30 min of 




Raw 264.7 (mouse macrophage cell line), Jurkat (human leuke-
mic T-cell line), Hmy (human B lymphoblast cell line), and HL60 
(human promyelocytic leukemia cell line) were purchased from 
ATCC (American Type Culture Collection, Middlesex, UK). 
All lines were cultured in RPMI supplemented with 10% (v/v) 
of heated-inactivated FBS, 2 mM glutamine, and 100 U/mL of 
penicillin/streptomycin, at 37°C in a 5% CO2 atmosphere. Cells 
were split every other day to maintain 70–80% confluent cultures.
Human peripheral blood mononuclear cells (hPBMCs) were 
obtained from three healthy voluntary donors. To separate mono-
nuclear cells, 15 mL of EDTA-anticoagulated blood was diluted 
with 15 mL of PBS and centrifuged (180 g, 30 min, 20°C) through 
a Ficoll-Hypaque gradient using a 7:3 ratio (diluted blood:ficoll). 
Mononuclear cells were collected at the interface between the 
ficoll and the plasma and washed twice by centrifugation (100 g, 
5 min, 20°C) with complete medium.
Cell Viability Assay: xCELLigence® System
An xCELLigence® RTCA DP Instrument (Roche Diagnostics, 
Penzberg, Germany) was used according to the manufacturer’s 
instructions to analyze cell viability. Raw 264.7 cells were cul-
tured at a density of 1.5 ×  104 cells/well with 200  µL of RPMI 
supplemented with 10% FBS until they reached the exponential 
phase (37°C and 5% CO2) (around 18 h). The different prototypes 
were added in a range of six different concentrations from 250 
to 7.8  µg/mL. As negative controls, cell culture media and the 
blank nanosystems were added to the wells. The impedance was 
monitored at 15 min intervals for 72 h.
Cellular Uptake by Macrophages
To evaluate the internalization of the nanosystems by fluorescence 
microscopy, 1 × 105 of Raw 264.7 cells were seeded in an NUNC 
96-Well Optical-Bottom Plates with Coverglass Base (Thermo 
Fisher Scientific, Langenselbold, Germany) with RPMI 10% FBS 
in the presence and absence of the fluorescent prototypes at 10 
and 50 µg/mL of the constituent polymer and the correspond-
ing amount of NE for 30 min. Three washes were performed to 
remove the excess nanosystems, and cells were observed with an 
inverted fluorescence microscope (IX50, Olympus Optical Co. 
GmbH, Hamburg, Germany).
A similar protocol was followed to perform the flow cytom-
etry analysis. In this case, after incubation with the fluorescently 
labeled prototypes followed by three washes with PBS, cells were 
detached using Accutase® (10 min, 37°C and 5% CO2). Finally, 
cells were washed once with complete medium to inactivate 
Accutase®, and the suspension was analyzed by flow cytometry 
(Accuri Cytometers, Ann Arbor, MI, USA).
A kinetic and more detailed study of the internalization was 
carried out by Confocal Laser Scanning Microscopy (Leica SP5) 
using the High Content Screening Automation HCS A module 
and the LAS AF MATRIX software. Images were acquired every 
5 min during 3 h.
Cytokine Profile Evaluation
Cytokine production was assessed by incubating 2 × 105 hPBMCs 
during 24 h in 96-well plates (37°C, 5% CO2) in the presence of 
the prototypes at two different concentrations: 10 and 100  µg/
mL. As negative and positive controls, cells were incubated with 
complete medium or with a combination of a solution of 1 µg/
mL of LPS and 10 µg/mL of PHA, respectively. After 24 h, the 
plate was centrifuged (100 g, 5 min, 4°C), and supernatants were 
collected and stored at −20°C before analysis. The cytokine levels 
(IL-12p70, INFγ, IL-2, IL-10, Il-8, IL-6, IL-4, IL-5, IL-1β, TNFα, 
and TNF β) were quantified using the FlowCytomix kit Th1/
Th2 according to the manufacturer’s instructions. Briefly, 25 µL 
of antibody-coated microspheres was incubated with 25  µL of 
culture supernatants and 50 µL of biotin-conjugated secondary 
antibodies (2  h, RT) using a microplate shaker. After several 
washes, 50 µL of streptavidin conjugated to phycoerythrin and 
100 µL of PBS-T were added to the preparation and incubated 
on a microplate shaker (1 h, RT). Finally, phycoerythrin-bound 
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beads were studied by flow cytometry (FC500, Beckman Coulter, 
Miami, FL, USA), and data were analyzed using FlowCytomix 
Pro 3.0 Software (eBioscience, San Diego, CA, USA).
ROS Production
The production of intracellular ROS was detected by measuring 
the oxidation of 2′,7-dichlorofluorescein diacetate (DCFH-DA). 
This marker can be oxidized by ROS and converted to a fluores-
cent compound.
The human promyeloblast cell line HL60 was used to 
evaluate the production of ROS. 2.5 × 105 cells were cultured in 
24-well plates in contact with 10 or 100 µg/mL of the different 
prototypes after 1 and 12 h. As negative and positive controls, 
complete medium and a solution of 10 µM of PMA were used, 
respectively. After this incubation step, cells were collected and 
centrifuged (100 g, 5 min) and resuspended in PBS containing 
5  µM of DCFH-DA. Afterward, the samples were incubated 
at 37°C during 30  min. Finally, cells were washed twice with 
PBS and analyzed by flow cytometry (Accuri Cytometers, Ann 
Arbor, MI, USA). The median of the fluorescence intensity was 
normalized to the negative control.
Activation Markers
Changes in the pattern of expression of membrane markers 
were studied in hPBMCs (CD3, CD19, CD71, and HLA-DR). 
2 × 105 cells were seeded in a 96-well plate and incubated with 
and without the nanosystems at two different concentrations (10 
and 100 µg/mL of the constituent polymer and the corresponding 
amount of the NE) during 24 h. As a positive control, a solution of 
10 µg/mL of PHA was used. Cells were labeled with the antibodies 
during 30 min at 4°C. In a final, the cells were washed twice with 
PBS and analyzed by flow cytometry (FC500, Beckman Coulter, 
Miami, FL, USA).
Routes of Activation. MAP Kinases and NFκB
The study of the signaling pathway activation (ERK1/2, p38, 
SAPK/JNK and NFκB) was performed with the human tumoral 
cell lines Jurkat and Hmy. These two cell lines were incubated 
with 10 µg/mL of the constituent polymer of PR NCs and PARG 
NCs for 1 and 3 h.
To perform the Western blot analysis, cells were washed with 
PBS and then suspended in a lysis buffer (Tris–HCl 10  mM, 
pH 8, NaCl 150  mM, EDTA 2.5  mM and 1% NP-40) contain-
ing a protease and phosphatase inhibitor (Complete Mini and 
PhosphoStop from Roche Ltd., Basel, Switzerland). Cell lysates 
were centrifuged (16,000 g, 4°C, 5 min) using an Eppendorf 5415R 
centrifuge (Eppendorf AG, Hamburg, Germany) to remove cell 
residues.
Cell extracts were loaded onto a 10% SDS-PAGE gel and 
transferred to a PVDF membrane using the Transblot-Turbo 
Transfer System (Bio-Rad, Hercules, CA, USA). PVDF mem-
branes were blocked with 5% of non-fat dried milk in TBST 
(1  h, RT). Membranes were washed and incubated overnight 
at 4°C with specific rabbit monoclonal antihuman p-ERK, p-, 
and p-SAP/JNK antibodies to determine the phosphorylation 
of ERK, p38, and SAP/JNK kinases (dilutions from 1:10,000 to 
1:20,000 in TBST) and with anti IKBα (1:10,000), which is the 
NFκB inhibitor, to evaluate its activation indirectly. After inten-
sive washes, membranes were incubated with the anti-GAPDH 
antibody as internal control (1:40,000) for 1  h at RT. Goat 
anti-rabbit IgG antibodies conjugated to HRP diluted 1:50,000 
in TBST with 2.5% of skimmed milk were used as secondary 
antibodies.
Membranes were revealed with the Clarity Western ECL 
Substrate (Bio-Rad Laboratories Inc.), and the protein bands 
were analyzed and quantified using the ChemiDoc XRS imaging 
system (Bio-Rad Laboratories Inc.).
In Vivo studies
Animals
Female BALB/c mice (4–5 weeks old) were housed in filter-top 
cages with a 12 h light/12 h dark cycle with a constant temperature 
environment of 22°C. Food and water were provided ad libitum.
Groups of five animals were randomly distributed and immu-
nized twice (0 and 28 days) with 60 µL of PR NCs or PARG NCs 
incorporating 10  µg of rHBsAg. The injection was performed 
intramuscularly (i.m.) in the hind leg of the mouse and rHBsAg 
adsorbed to aluminum hydroxide was used as a positive control. 
Aluminum hydroxide and rHBsAg solutions were incubated in a 
volumetric ratio of 3:1 (rHBsAg:alum) for 30 min at 4°C under 
moderate agitation. The suspension was centrifuged (10,000  g, 
10 min, 4°C), and the pellet was resuspended in a suitable volume 
of isotonic saline solution. Blood samples were collected from the 
mouse maxillary vein at 6 and 10 weeks for the quantification of 
HBsAg-specific antibodies.
Quantification of rHBsAg-Specific IgG and IgG 
Subtypes by ELISA
96-Well plates were coated with rHBsAg diluted in carbonate 
buffer (pH 9.6) at a concentration of 5  µg/mL and incubated 
overnight at 4°C. The plates were then blockaded with PBS-BSA 
1% for 1  h at 37°C to reduce the non-specific interactions. A 
mouse monoclonal IgG anti-HBsAg was used to quantify the 
levels of specific rHBsAg IgG: the μg/mL of the specific IgG 
were converted into international units using a solution of anti-
HBsAg rabbit IgG with a known concentration into mIU/mL. 
The controls and a pool of serum samples from each group were 
serially diluted and incubated for 2  h at 37°C. Two secondary 
antibodies (goat anti-mouse and anti-rabbit IgG conjugated 
with HRP) were added and incubated with the samples for 1 h 
at 37°C. Bound antibodies were revealed with 2,2′-azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) (ABTS), and the optical 
density was read at 405 nm.
To calculate the ratio IgG1/IgG2a, a pool of sera collected from 
the immunized mice were analyzed using the same ELISA proto-
col, but using the goat anti-mouse IgG1 and IgG2a (conjugated to 
HRP) as secondary antibodies.
Restimulation of Splenocytes Ex Vivo for Quantitative 
PCR (qPCR) Gene Expression Assays
Changes in gene expression were evaluated by qPCR using 
TaqMan® Gene Expression Assays for several genes and the 
TaqMan® Fast Advanced Master Mix from Life Technologies™. 
TaBle 1 | Physicochemical characterization of the selected nanocapsules (NCs).
Formulation abbreviation size (nm) PDi Zeta potential (mV) rhBag association (%)
Nanoemulsion NE 264 ± 10 0.2 –23 ± 2 –
Chitosan nanocapsules CS NCs 456 ± 2 0.3 +47 ± 2 –
Protamine nanocapsules PR NCs 274 ± 4 0.2 +27 ± 4 –
rHBsAg-loaded protamine nanocapsules PR NCs-rHBsAg 358 ± 20 0.3 +5 ± 4 74 ± 5
Polyarginine nanocapsules PARG NCs 251 ± 2 0.1 +30 ± 2 –
rHBsAg-loaded polyarginine nanocapsules PARG NCs-rHBsAg 320 ± 8 0.3 +15 ± 1 70 ± 7
PDI, polydispersity index; HBsAg, hepatitis B surface antigen.
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The qPCR was performed in a 7900HT Fast Real-Time PCR 
System (AB, Life Technology Co.).
Mice previously immunized with two intramuscular doses 
(0, 4  weeks) were sacrificed at the end of the study (11  weeks 
after the first immunization). To obtain cell suspensions, spleens 
were removed under sterile conditions, and cells were dissoci-
ated by gentle teasing in complete medium (DMEM with 10% 
FBS) and filtered with a cell strainer (Falcon, NJ, USA). The 
suspension was centrifuged (100 g, 5 min), and the pellet was 
resuspended in 7 mL of DMEM. The same protocol followed to 
obtain hPBMCs was carried out to eliminate spleen erythrocytes 
and granulocytes.
Mononuclear cells separated by gradient centrifugation at a 
concentration of 5 × 106 cells/mL were restimulated with 10 µg/
mL of rHBsAg for 12 or 24 h. RNA was extracted and purified 
using the ReliaPrep™ RNA Miniprep Systems kit (Promega), and 
genomic DNA was eliminated with the same kit. The cDNA was 
synthetized using the Maxima First Strand cDNA Synthesis kit 
(Thermo Fisher Scientific Inc.). To check the optimal concentra-
tion of cDNA per sample, a qPCR for GAPDH was previously 
performed at different dilutions.
Data from three mice per group were normalized to the 
internal control GAPDH, and ΔΔCt was calculated using as a 
baseline the control data from mice immunized with PBS 1× and 
restimulated in vitro with rHBsAg. These data were averaged, and 
relative quantification (RQ) was calculated.
statistical analysis
Results are presented as Mean ± SD. Statistical comparisons were 
made by the Mann–Whitney U test for in vivo experiments and 
T test for in vitro experiments. The accepted level of significance 
was a p value < 0.05.
ethical issues
Institutional ethics approval to work with human samples 
from healthy donors was obtained from the Ethics Committee 
for Clinical Research (Xunta de Galicia, Spain, 2013/272). All 
participants included in the study gave their written informed 
consent.
All protocols developed with mice were adapted from the 
guidelines of the Spanish regulations (Royal Decree 53/2013) 
regarding the use of animals in scientific research and under 
the approval of the Ethical Committee of the University of 
Vigo.
resUlTs anD DiscUssiOn
Development and characterization of 
Polymeric ncs
The method selected for the preparation of the nanostructures 
was the solvent displacement technique previously described 
by our research group (16). The procedure is based on the 
nanoprecipitation of the lipid components upon the diffusion 
of a polar solvent into an aqueous phase, where the cationic 
polymer interacts with the oily nanodroplet cores, thus forming 
a polymeric coating that surrounds the oily core. Polycationic 
NCs made of CS (11, 14), PARG (17) and PR (12) with dif-
ferent oil/surfactant ratios were previously developed by our 
research group. In this work, the type and the ratio of the 
lipidic constituents were adjusted to develop nanocarriers with 
the identical oily core composition but varying the polymeric 
surface coatings. As a result, three different NC formulations 
and the corresponding negatively charged NE were developed 
(Table  1). As expected, the three NC formulations had a 
positive zeta potential and their size varied depending on the 
nature of the polymer shell. PR and PARG NCs presented zeta 
potential values close to +30 mV, whereas the value for CS NCs 
was higher (+47 mV), probably due to the presence of a larger 
number of positive groups on their surface. With respect to the 
particle size, PR or PARG NCs had similar sizes, within the 
range 250–300 nm, and a low PDI (0.2 and 0.1, respectively). By 
contrast, CS NCs had a larger size and higher PDI (456 ± 2; 0.3). 
This result can be explained by the different entanglement of the 
tensioactive agents (PEG-stearate and sodium cholate) with the 
cationic polymers at the interface of the oily cores. In fact, CS 
NCs with reduced sizes could also be produced by adjusting the 
surfactant composition (11).
loading of rhBsag antigen Onto the ncs
Based on the results obtained in the different cellular studies, 
PR and PARG NCs were selected for loading with rHBsAg. The 
incorporation of the antigen into the nanostructure surface was 
attributed to electrostatic forces occurring between the cationic 
polypeptide of the polymer coating and the negatively charged 
antigen (−20 mV), as well as to hydrophobic interactions between 
the antigen and the tensioactive molecules. To associate rHBsAg 
to the NC surface, the antigen solution was incubated with the 
previously isolated NCs (11). The mass ratio selected was 4:1 
(theoretical concentration of the cationic polymer adsorbed into 
FigUre 1 | Complement activation of human plasma induced by the nanostructures. Different concentrations of the prototypes were tested by Western blot: 10, 
100, and 1,000 µg/mL. Phosphate-buffered saline and cobra venom factor (CVF) were selected as negative and positive controls. Abbreviations: NE, nanoemulsion; 
CS NC, chitosan nanocapsule; PARG NC, polyarginine nanocapsule; PR NC: protamine nanocapsule. Bands corresponding to the C3 protein and C3 split products 
are indicated. Molecular weight controls are expressed in kilodalton. The lower graph corresponds to the intensity of the lower band (C3 cleaved) normalized to the 
negative control. The median ± SD is represented (n = 3). *Significant differences between negative and positive (CVF) controls or nanocapsule treatments.
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the NC surface:rHBsAg). Quantification of the non-associated 
antigen was performed by ELISA. Both prototypes showed an 
association efficiency greater than 70% (Table 1). Regarding the 
physicochemical properties of the nanostructures, the associa-
tion of the antigen to the NC surface led to a size increase and a 
decrease in the zeta potential. These changes support the presence 
of the antigen on the NC surface, a location that would theoreti-
cally facilitate recognition by antigen-presenting cells (18, 19).
activation of the complement cascade
The complement system is one of the most important constitu-
ents of the innate humoral system. It includes different serum 
proteins that are activated in cascade upon contact with different 
stimuli. Three different routes (classic, alternative, and lectins) 
can activate this system, and the degradation of the C3 is a com-
mon step in all of them. The stimulation and the consequent 
activation of the cascade can promote phagocytosis processes, it 
can mediate inflammation, and it is involved in the recognition 
and clearance of pathogens (20). The complement serves as a 
first line of defense, and it plays an important role in promot-
ing antigen-specific responses by enhancing both B- and T-cell 
immunity (21). In fact, the bioactivity of alum (the most used 
adjuvant in vaccines worldwide) is strongly related to its ability 
to activate the complement cascade (22).
Analysis of the C3 degradation by Western blot showed that 
PR NCs slightly induced the activation of the complement cas-
cade. The highest rate of activation was achieved at the highest 
concentration tested (1  mg/mL of theoretical concentration of 
protamine), and the degradation rate was double that found in 
the negative control (Figure  1). This result was confirmed by 
ELISA using the quantification of the C5a factor levels, which 
were two times higher in the plasma exposed to the NCs than in 
the untreated negative control (data not shown).
It has been previously reported that the nanoparticle surface 
composition plays a crucial role in the complement cascade acti-
vation: the presence of a high surface density of amino groups 
in the polymer chain can enhance the interaction with the C3b 
α-chain (23). PR and PARG are guanidine-rich polymers, and 
they would be expected to activate the complement cascade. By 
contrast, the results on the complement activation properties of 
chitosan reported to date are quite variable (24, 25), probably due 
to the different types and sources of chitosan on the market. In 
our case, activation was not observed after contact between this 
polymer and the complement cascade proteins.
FigUre 2 | Effect of the prototypes on the viability of Raw 264.7 cells. Cells were cultured until their exponential phase, and then the nanostructures were added 
(indicated with an arrow) at different concentrations. IC50 was calculated with RTCA Software 1.2.1. Abbreviations: NE, nanoemulsion; CS NC, chitosan 
nanocapsule; PR NC, protamine nanocapsule; PARG NC, polyarginine nanocapsule.
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Western blot analysis showed that only PR NCs, and not 
PARG NCs, were able to achieve significant levels of the C3 
split products at the highest concentration tested. This finding 
suggests that another mechanism, besides the interaction with 
the C3b α-chain, may be contributing to the activation of the 
complement cascade. This difference could also be attributed to a 
higher percentage of adsorption of the PR when compared with 
the PARG. Further investigation need to be perform to validate 
this hypothesis. Although little is known about the mechanism 
of complement activation induced by arginine-rich polymers, it 
has previously been reported that PR, which is commonly used to 
neutralize the effect of heparin after cardiopulmonar bypass, can 
induce complement cascade activation through the classic route 
when heparin–PR complexes are formed (26).
In Vitro cell studies
Cell Viability
Six different concentrations of the nanosystems (from 250 to 
7.8 µg/mL) were used to evaluate the cell viability. As shown in 
Figure 2, a dose-dependent trend was observed for all formula-
tions. PARG NCs reduced cell viability to a greater extent than 
the other prototypes, with an IC50 close to 30 µg/mL, followed by 
PR NCs > NE > CS NCs. A major reduction in the cell viability 
has been previously reported with NCs presenting PARG in the 
surface composition, being this toxicity reported as dose depend-
ent and influenced by the composition of the nucleus (27). In 
addition, it has previously been reported that the toxic effect 
induced by nanoparticles decreases with increasing particle size 
(28). This may explain why CS NCs are the prototype that reduces 
less the cell viability. In the case of the NE, this prototype was only 
able to reduce the cell viability at the higher concentrations tested: 
the negative charge on the surface may play an important role in 
the reduction of cell viability (29, 30).
Cellular Uptake and ROS Production by 
Macrophages
Fluorescence microscopy and flow cytometry results (Figure 3) 
indicate that all prototypes were efficiently internalized by the 
cells in a dose-dependent manner. A real-time uptake study using 
Confocal Laser Scanning Microscopy and the High Content 
Screening Automation HCS A module was performed by incu-
bating macrophages with fluorescent NCs during 90 min. All of 
the prototypes were quickly internalized, and the fluorescence 
was detected after 15  min from the starting time point of the 
experiment (Figure 4). The fluorescence intensity increased up 
to the last time point of the experiment.
It has been reported in the literature that particulate delivery 
systems are commonly taken up by phagocytic cells and that this 
internalization is dependent on particle size, composition, and 
surface charge (31–33). In general, charged large particles are 
internalized more rapidly than small neutral particles, with the 
cationic prototypes being particularly prone to uptake within 
FigUre 3 | Internalization of the fluorescent nanostructures by Raw 264.7 cells. Left: cells incubated with the fluorescent prototypes (images taken on a 
fluorescence microscope) at 10 and 50 µg/mL. Right: cells analyzed by flow cytometry (a) by histograms (B) by the median of the fluorescence intensity (MFI). 
Abbreviations: NE, nanoemulsion; CS NC, chitosan nanocapsule; PR NC, protamine nanocapsule; PARG NC, polyarginine nanocapsule.
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charged systems (34). In this study, all the formulations are 
charged, positively or negatively, and have proven to be effi-
ciently internalized. The charge, regardless of its sign, may have 
facilitated capture by macrophages: while cationic nanoparticles 
would have easily interacted with anionic cell surfaces, the inter-
nalization of anionic NEs may have occurred through the non-
specific binding of the particles on cationic domains followed 
by endocytosis (35). It has been described in other polymeric 
nanomaterials, that once they are internalized in endosomes, 
they go to lysosome where they are processed. They can induce 
ROS production, and eventually, trigger the immune response 
(36–38). In addition, it has been reported that ROS production 
by the dendritic cells plays an important role in the antigen 
presentation in that it stimulates the cross-presentation in these 
cells and therefore it enhances the CD8+ T lymphocyte responses 
(39). As a consequence, ROS production in the promyelocytic 
cell line HL60 was studied as a measure of cell activation after 
the internalization of these prototypes, where the cell activation 
was at the same time an indicator of the initiation of the adaptive 
immune response.
The ROS production was studied after cell exposure to nano-
structures during 1 or 12 h (Figure S3 in Supplementary Material). 
All the prototypes induced the production of ROS in a dose- and 
time-dependent manner. It has been previously reported that 
the induction of ROS by inorganic nanoparticles could be a 
mechanism for the promotion of cell death (40). However, little 
is known about ROS production by polymeric nanoparticles as a 
mechanism of cell defense against infections.
Cytokine Profile Evaluation
Cytokines are peptides, small proteins, or glycoproteins that play 
an important regulatory role in several biological processes. They 
FigUre 4 | Kinetic internalization study of the labeled nanostructures performed on a confocal microscope [red channel: rhodamine 6G (labeled nanocapsules); 
blue channel: DAPI (nucleus)]. Raw 264.7 cells were incubated in the presence of the nanosystems, and images were acquired every 5 min. Images at 15, 30, 60, 
and 90 min are shown. Abbreviations: NE, nanoemulsion nanocapsule; CS NC, chitosan nanocapsule; PR NC, protamine nanocapsule; PARG NC, polyarginine 
nanocapsule.
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are produced mainly by immune cells, but also by several other 
cell types. Cytokines are the main messengers between cells of 
the immune system and they regulate the innate and adaptive 
responses and also modulate the inflammatory response (41). 
In this study, our main goal was to investigate if the NCs, to be 
used as antigen carriers, are inherently able to stimulate cytokine 
secretion by hPBMCs.
It can be seen from the results in Table 2 that the PR and 
PARG NCs have a slightly greater tendency to induce the 
production of pro-inflammatory cytokines than CS NCs or the 
control NE. The main difference was observed in the secretion 
of TNFα, where two out of the three donors responded in the 
case of PR and PARG NCs, only one out of three donors was 
positive for CS NCs, and no positive response was observed 
for the control NEs. Although these responses are not remark-
able, they are in agreement with previous studies in which it 
was found that protamine and PARG are able to induce the 
production of TNFα; PR was included in a nanoparticulate 
form and incorporated CpG (42), while in the case of PARG it 
was the bulk material (43). On the other hand, it has also been 
reported that cationic particles are more efficient at inducing 
inflammatory responses than anionic or neutral particles (34). 
This observation is consistent with the overall cytokine profiles 
observed for the three types of NCs. By contrast, the anionic NE 
was only able to induce the production of IL-8, a cytokine that 
is basally produced at high levels (Table 2). The differences in 
the cytokine secretion profiles for the three cationic prototypes 
could be explained by the smaller size of PR and PARG NCs 
when compared with CS NCs: the higher specific surface area 
may contribute to a more efficient interaction with the mono-
nuclear cells (44).
The cytokine profile induced by PR and PARG prototypes 
is dominated by IL-6, Il-1β, IL-8, and TNFα (at the highest 
dose tested). All of these cytokines are mainly produced by 
macrophages when they are exposed to inflammatory stimuli 
(45). While IL-8 is a potent chemotactic factor for lymphocytes 
and neutrophils that is often released during phagocytosis, IL-6 
induces B cell differentiation and increases antibody titers (46, 
47). In addition, IL-1β is released upon activation of macrophages 
via Caspase 1 pathway, and similarly to this one, TNFα is also an 
endogenous pyrogen that is produced and released at the early 
stages of the immune response to infections (45). Both prototypes 
have proved to be efficiently internalized by phagocytic cells 
(Figures 3 and 4), hence a high internalization rate during the 
first steps of the immune response may have contributed to the 
activation of human monocytes, leading to the release of all these 
pro-inflammatory cytokines generating an adequate scenario to 
initiate a specific immune response.
TaBle 2 | Cytokine production by human peripheral blood mononuclear cells 
incubated with nanocapsules at two doses (10 and 100 µg/mL).
μg/ml ne cs ncs Pr ncs Parg lPs-
Pha
Th1 profile IL-2 10 – – – – ++
100 – – – ++1/3
IL-12p70 10 – – – – +++
100 – – – –
IFN γ 10 – – – ++1/3 +++
100 – – – –
TNF β 10 – – – – +
100 – – – –
TNF α 10 – – – – +++
100 – +1/3 +2/3 +2/3
Th2 profile IL 4 10 – – – – +
100 – – – –
IL 5 10 – – – – +
100 – – ++1/3 ++1/3
IL 10 10 – – – – ++




IL 1β 10 – – – – +
100 – +1/3 + +
IL 6 10 – – – – +++
100 +1/3 ++ +++ ++
IL 8 10 +1/3 – +1/3 +2/3 +
100 + + + +
NE, nanoemulsion; CS NC, chitosan nanocapsule; PR NC, protamine nanocapsule; 
PARG NC, polyarginine nanocapsule.
The positive control was lipopolysaccharide (LPS) (1 µg/mL) with phytohemagglutinin 
(PHA) (10 µg/mL).
+: 1–10; ++: 10–100; +++: 100–1,000; ++++: >1,000-fold higher than negative 
control (cells incubated in culture media).
+N/tested: number of positive responsive persons/three donors tested.
FigUre 5 | Modulation of activation markers (CD71 and HLA-DR) in gated T (CD3+) and B (CD19+) lymphocytes (top and bottom graphs, respectively) from human 
peripheral blood mononuclear cells (hPBMCs) incubated with the prototypes (at 10 and 100 µg/mL). Percentages of CD71–HLADR+, CD71+HLADR–, and 
CD71+HLADR+ cells are represented. The results are the average of three independent experiments with hPBMCs from three different healthy donors (*p < 0.05).
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Activation Markers
Human CD71 (transferrin receptor) and class II molecules 
of the major histocompatibility complex (HLA-DR) are 
membrane markers that can be modulated during cell activa-
tion. Transferrin receptor is expressed at different levels in 
many cell types and increases its expression in activated cells 
such as T and B lymphocytes, because this mechanism is used to 
import extracellular iron for metabolic needs (48, 49). HLA-DR 
is constitutively expressed in B cells and it has been shown to 
be down regulated under certain stimuli. The modulation of 
this marker changes depending on the stage of differentiation 
of the B cells upon its activation. While an increase during the 
first contact with stimuli is commonly observed, a decrease 
occurs during the last steps of differentiation (50–52). On the 
other hand, T  cells do not express HLA-DR unless they are 
activated (53).
The expression of the activation markers CD71 (transferrin 
receptor) and HLA-DR in T (as CD3+) and B (as CD19+) cells 
incubated with the different nanostructures at two different 
doses (10 and 100  µg/mL) was evaluated by flow cytometry 
(Figure 5). The results indicate that only PARG NCs were able to 
increase the percentage of CD71+HLA-DR+ T cells and also the 
expression of CD71 in B cells. Furthermore, PARG NCs induced 
the modulation of HLA-DR in B cells. While this effect seems to 
correlate to cell activation, it cannot be excluded that a cytotoxic 
effect could have been the responsible for this modulation in 
the expression of these markers as consequence of exposure to 
damage-associated molecular patterns (DAMPs, danger signals, 
or alarmins). In fact, these molecules have been described as the 
possible responsibles for the adjuvant effect of other molecules 
such as alum (54).
These results are in agreement with the cytokine data, where 
PARG NCs induced the production of different cytokines in 
hPBMCs. A synergistic effect of all of these cytokines may play a 
crucial role in the lymphocyte activation and subsequently in the 
modulation of markers such as CD71 or HLA-DR.
FigUre 6 | Reduction in IκBα expression and activation of mitogen-activated protein kinases [p-extracellular signal-regulated kinase (ERK), p38, and p-SAP/c-Jun 
NH2-terminal kinases (JNK)] and the nuclear factor κB pathway in Jurkat and Hmy cell lines induced by PR NCs and PARG NCs after 1 h (a) or 3 h (B) of 
incubation. GAPDH was used as a loading control. White space between lanes shows the cut point in membranes.
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Routes of Activation. MAP Kinases
Mitogen-activated protein kinases (MAPKs) are a protein fam-
ily that is involved in several processes such as gene expression, 
mitosis, cell migration, metabolism, and programmed cell death. 
MAPKs are activated through the phosphorylation of certain 
residues and, in turn, they activate their target proteins, includ-
ing other protein kinases, transcription factors, or cytoskeleton 
proteins.
The MAPK families that are most widely reported in the 
literature are the ERK, the c-Jun NH2-terminal kinases (JNK), 
and the p38 family. While ERKs are involved in the regulation 
of processes such as mitosis or meiosis, JNK are mainly involved 
in the control of programmed cell death or apoptosis. On the 
other hand, p38 participates in the immune response activation 
(55). In addition, the NFκB is a transcription factor that plays an 
important role in the regulation of certain immune responses by 
modulating the expression of receptors or surface adhesion mol-
ecules, inflammatory cytokines, and chemokines. Furthermore, 
it is involved in the response to stress signals and in cell survival 
(56, 57).
In this study, we investigated the capacity of PR and PARG 
NCs to induce the secretion of MAPK and NFκB in two different 
cell lines, namely, the Jurkat (human leukemic T-cell line) and the 
Hmy (human B Lymphoblast cell line) cell lines. It has previously 
been reported that activation of the NFκB pathway leads to the 
degradation of the IKBα inhibitor and therefore a decrease in 
IKBα was expected in these cells.
The Western blot analysis only showed a slight increase in the 
phosphorylation levels of the p38 family after 3 h in contact with 
PARG NCs (Figure 6). Considering Hmy and Jurkat cell lines as 
representative B and T cells, respectively, of the main PBMCs, 
this result could correlate with the observed capacity of these 
NCs to induce the production of Il-1β, IL-6 and IL-8 in human 
PBMC, as it is known that the p38 family is activated in response 
to different inflammatory cytokines and the triggering of dif-
ferent immune responses (55, 58, 59). In addition, p-p38 has 
also been shown to be involved in the proliferation of Th1 cells 
(60). This explains why p38 is activated mainly by PARG NCs, 
as this NCs formulation showed a Th1 profile characterized by 
the production of TNFα.
In the case of ERK, both prototypes, PR and PARG NCs, 
induced its activation in Hmy and Jurkat cells, with this effect being 
time dependent only in Jurkat cells (Figure 6). ERK is activated 
in response to several cytokines, and it is involved not only in 
cell survival but also in cell differentiation (55). In addition, ERK 
phosphorylation is an important step during both T and B cell 
activation (61, 62) and in the Th2 differentiation process (63).
Regarding p-SAP/JNK, activation was not detected upon 
contact with any of these prototypes (Figure 6). This fact can be 
explained by the pro-apoptotic activity of the p-SAP/JNK family: 
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the lack of activation was expected (58, 64) since none of the 
prototypes showed a cytotoxic effect at low doses and in short 
periods of time.
The activation of NFκB was detected by the decrease in 
its IkBα inhibitor levels (Figure  6). This fact was observed 
in both Jurkat and Hmy cells and with both protamine NCs 
and PARG NCs. NFκB is activated by a wide range of signals 
such as antigen receptors, pattern-recognition receptors, and 
different TNF and IL-1 receptors. This activation regulates not 
only the innate but also the adaptive immunity and different 
inflammatory responses (65). The decrease in the IkBα levels in 
both Jurkat and Hmy cell lines upon contact with this immune 
stimulator was expected considering that this transcription 
factor is essential to trigger some processes related to immune 
cell activation.
In light of the results obtained, it can be concluded that PR 
and PARG NCs are able to induce the phosphorylation of p38 and 
ERK, as well as the degradation of IκBα in both T and B cell lines, 
with PARG NCs having a slightly superior activation capacity.
Overall, data obtained by in  vitro studies, postulate PR and 
PARG NCs as the most promising prototypes as antigen delivery 
systems. On the other hand, NE and CS NC have not demon-
strated to be strong inducers of immune responses and do not 
activate the complement cascade, thus they could be useful as 
carriers intended to avoid the immune system recognition, for 
example to target cells for gene therapy (66).
In Vivo studies
Taking into account the results obtained in the in vitro studies, 
PARG and PR NCs were selected for the in vivo evaluation of their 
capacity to induce the production of an immune response against 
a model antigen, rHBsAg. To this end, groups of five Balb/C 
female mice were intramuscularly immunized with two doses of 
rHBsAg adsorbed onto PR NCs and PARG NCs or alum. The 
humoral-specific immune response (anti-rHBsAg serum IgG) 
and the type of immune response elicited (measured by the IgG1/
IgG2a ratio) were both analyzed. In addition, a panel of several 
genes involved in immune responses was studied ex vivo in cells 
from immunized mice.
Immune Response Elicited by Immunostimulating 
rHBsAg-Loaded NCs
It can be seen from the results in Figure 7 that PR NCs and PARG 
NCs were able to elicit antigen-specific antibody levels at 6 weeks 
after immunization, with levels close to 400 and 130 mIU/mL, 
respectively. These levels increased slightly to 500 and 200 mIU/
mL, respectively, after 10 weeks. It is worthy to note that in both 
cases, seroprotection levels (>100  mUI/mL) were achieved, 
although this increase was not as high as the one observed in 
control mice immunized with alum-rHBsAg (from 1,100 to 
1,600 mUI/mL) (Figure 7).
Despite the response induced by the marketed alum-rHBsAg 
vaccine was much higher, the average levels achieved by PR 
NCs and PARG NCs were over 100  mIU/mL, which has been 
established as the threshold of antibody protective levels in 
humans (67). It can also be stated that PR NCs showed better 
immunostimulant properties than PARG NCs as they induced 
higher specific antibody levels in mice (5/5). This difference can 
be explained by the higher ability of PR NCs to activate the com-
plement cascade compared with PARG NCs, which may play a 
crucial role in the adjuvant effect of the NC. Thus, independently 
on the NCs under study, the immune response induced by both 
prototypes could be due to a combination of several routes such 
as p38 and ERK. Moreover, the lack of a strong activation of the 
FigUre 7 | Systemic immune response upon intramuscular immunization with rHBsAg PR NCs and PARG NCs. The top graphs represent individual IgG 
concentrations of anti-HBsAg (expressed in mUI/mL) in each mouse (triangles) and the average of five mice (dash) at 6 weeks (left graph) and 10 weeks (right graph) 
after the first administration. The number of mice with antibody levels over 100 mIU/mL and the IgG1/IgG2a ratios at different time points are also represented in the 
lower table.
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NFκB pathway could be related to the moderate in vivo immune 
response obtained in the presence of NCs.
Modulation of the Immune Response
To determine the type of response induced by these prototypes, 
the IgG1/IgG2a ratio was calculated for both prototypes. These 
two IgGs were selected because while the IgG2a subtype is related 
to cellular immune responses mediated by Th1 lymphocytes, 
IgG1 is mostly produced after Th2 activation, which mediates the 
humoral immune response.
Both humoral and cellular responses were elicited by both 
prototypes. The highest levels detected for Th2, with ratios rang-
ing from 2.6 to 1.7. While this ratio did not change over time for 
PR NCs, it decreased slightly for PARG NCs, which indicates 
that an increase in Th1 response had occurred (Figure 7). This 
finding is in agreement with the combination of cytokines pro-
duced by hPBMCs upon contact with PARG NCs and also due 
to the activation of both p-ERK and p-p38, which are commonly 
involved in Th2 and Th1 responses, respectively (60, 63). The 
same trend was observed in the control group, although in this 
case the initial IgG1/IgG2a ratio was higher (close to 5). This is 
in agreement with the known fact that alum is a very effective 
Th2 activator (68).
Gene Expression Assays in Restimulated 
Splenocytes From Immunized Mice
To understand the mechanism involved in the immunostimulant 
properties of PARG NCs and PR NCs, the expression of different 
genes was studied by qPCR. For this purpose, splenocytes from 
immunized mice were restimulated with the HBsAg during 12 or 
24 h. RNA from these cells was extracted to analyze the expres-
sion of genes involved in apoptosis and inflammation (Caspase 1, 
3, 8, and 9; Fas and Bcl2) of different cytokines (IL-10, 1L-4, IL-2, 
INF-γ, IL-6, TNF-α, IL-1β, and IL-17) and of certain activation 
markers (CD74, B2M, CD71, CD69, CD154, CD80, and CD86). 
The results of these studies are summarized in Table 3, and the 
values highlighted in red show an increase in the RQ value greater 
than 2. Significant differences were only registered for IL17A in 
mice immunized with PR NCs-HBsAg both 12 and 24  h after 
restimulation. A minor increase was also observed in IL-1β levels 
in the same group after 24 h of restimulation.
IL-17A is a cytokine produced by Th17  cells and by other 
immune cells, including γδ T cells, NKT cells, NK cells, neutrophils, 
and eosinophils. In fact, one of its functions is to connect innate 
and adaptive immune responses. IL-17A is a pro-inflammatory 
cytokine that induces the production of other cytokines and 
chemokines, which are crucial in the recruitment, activation, and 
migration of neutrophils to the site of inflammation. It has been 
reported that this cytokine is also involved in the development of 
germinal centers (GC) (69). IL-1β, which is produced through the 
NALP3 inflammasome route and whose release can be initiated 
by the complement cascade activation (70), is one of the major 
mediators of inflammation and it is the main known endogenous 
pyrogen. IL-1β is also very important in the initiation of innate 
immune responses and, as a consequence, it has a critical role in 
the control of pathogenic infections (71). Both cytokines IL-17 
TaBle 3 | Changes in the expression of selected genes in splenocytes from mice immunized with alum-rHBsAg, PRNC-rHBsAg, and PARGNC-rHBsAg restimulated 
for 12 or 24 h with rHBsAg.
gene name rQ (12 h) rQ (24 h)
alum-rhBsag Prnc-rhBsag Pargnc-rhBsag alum-rhBsag Prnc-rhBsag Pargnc-rhBsag
B2M Beta-2-microglobulin 0.93 0.71 0.91 0.98 1.28 0.82
TNF Tumor necrosis factor 1.12 0.95 1.16 1.16 1.38 0.74
IL10 Interleukin 10 0.80 0.69 0.89 0.76 1.17 0.65
IL4 Interleukin 4 1.10 0.73 0.88 1.07 1.62 0.79
IL2 Interleukin 2 1.28 0.92 0.96 0.92 1.58 0.73
INFγ Interferon gamma 0.92 1.03 1.19 0.84 1.26 0.69
IL6 Interleukin 6 0.93 0.81 1.04 0.89 1.24 0.72
IL1β Interleukin 1 beta 1.68 1.34 1.40 1.20 2.06 1.13
IL17A Interleukin 17A 1.72 2.30 0.91 2.18 3.11 0.46
CASP1 Caspase 1 0.94 0.81 1.01 1.43 1.36 1.05
CASP3 Caspase 3 0.88 0.80 0.91 1.33 1.26 0.88
CASP8 Caspase 8 1.02 0.80 0.92 1.18 1.14 0.89
CASP9 Caspase 9 0.82 0.77 0.83 1.43 1.25 0.91
Bcl 2 B-cell lymphoma 2 0.73 0.68 0.83 1.11 1.00 0.81
FADD Fas-associated protein with death domain 0.91 0.76 0.74 1.74 1.21 0.89
CD154 Cluster of differentiation 154 0.63 0.64 0.70 0.92 0.94 0.72
CD69 Cluster of differentiation 69 1.12 0.91 0.99 1.24 0.90 0.65
CD74 Cluster of differentiation 74 0.91 0.96 1.09 1.48 1.35 1.06
TFRC Transferrin receptor 0.88 0.80 0.90 0.96 1.32 0.90
CD86 Cluster of differentiation 86 1.09 0.83 0.94 0.02 1.50 1.00
CD80 Cluster of differentiation 80 0.69 0.91 0.88 1.19 1.30 0.79
Values in this table represent the RQ with respect to the control (splenocytes from mice immunized with phosphate-buffered saline 1× and restimulated in vitro with rHBsAg) 
calculated from independent data for 3 mice per group.
RQ values greater than 2 are represented in red (% CV of ΔCt < 25).
RQ, relative quantification; PR NC, protamine nanocapsule; PARG NC, polyarginine nanocapsule; rHBsAg, recombinant hepatitis B surface antigen.
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